Innovating For Patients
Trevena is a biopharmaceutical company focused on developing and commercializing novel medicines for patients with central nervous system (CNS) disorders.About Us
Trevena’s novel pipeline includes four product candidates that are being developed for areas of critical need in CNS disorders. All of the company’s pipeline assets are new chemical entities with unique mechanisms of action that target well-known receptors.
|Program||Molecular Target||Therapeutic Target||Current Phase||PC||PH1||PH2||PH3||NDA|
|Oliceridine||Mu receptor||Moderate-to-severe acute pain||NDA||Intravenous PC complete||PH1 complete||PH2 complete||PH3 complete||NDA in progress|
|TRV250||Delta receptor||Acute migraine||PH1||Oral/Subcutaneous PC complete||PH1 in progress||PH2 not started||PH3 not started||NDA not started|
|TRV734||Mu receptor||Opioid use disorder||PH1||Oral PC complete||PH1 in progress||PH2 not started||PH3 not started||NDA not started|
|TRV045||S1P receptor||CNS disorders||PC||Oral PC in progress||PH1 not started||PH2 not started||PH3 not started||NDA not started|